Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized, placebo-controlled study of MTPS9579A in asthma requiring inhaled corticosteroids and a second controller
2019-000795-41Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing MTPS9579A arm with Placebo arm (2 arms). Primary endpoint: Time to first composite event of asthma exacerbation or diary worsening. Started Sep 2019; status: completed.
02
Drugs
MTPS9579A
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-000795-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000795-41.